Board Meeting13 Aug 2026, 09:00 pm
Anlon Healthcare Approves Financials, Acquisitions, and Capital Increase
AI Summary
Anlon Healthcare Ltd's Board of Directors met on August 13, 2026, approving audited standalone and consolidated financial statements for FY26. Key decisions include the appointment of directors, an internal auditor, and a significant increase in authorized share capital from ₹110 Cr to ₹130 Cr. The company also approved two share swap agreements to acquire up to 44.94% of Apiqo Organics Private Limited and up to 47.41% of Bizotic Lifescience Private Limited through preferential issuance of equity shares.
Key Highlights
- Board approved FY26 audited financial statements.
- Authorized share capital increased to ₹130 Cr.
- Agreements to acquire stakes in Apiqo Organics and Bizotic Lifescience.
- Preferential issuance of equity shares for acquisitions approved.
- Director appointments and regularization approved.
Price Impact
More from AHCL